Global Menopause Drug Market Size, Trends, and Growth Opportunity, By Stages Type (Perimenopause, Menopause, Postmenopause), By Treatment Type (Non-Hormonal Treatment, Hormonal Treatment, Herbal Supplements), By Product Type (Patch, Pill, Gel, Injectable, Cream, Others), By Route of Administration Types (Oral, Injectable, Topical), By End-Users (Hospitals, Homecare, Specialty Clinics, Others), By Region (North America, Europe, Asia Pacific, Latin America, Middle East) and Forecast till 2030.
Global Menopause Drug Market
The Global Menopause Drug Market was valued at USD 15.8 billion in 2022 and is expected to expand to USD 24.1 billion in 2030 at a CAGR of 4.61% during the forecast period 2023-2030.
Menopause is a physiological process that occurs when a woman's body stops producing estrogen hormones and her menstrual cycles generally stopped. It may develop naturally or could be contracted as a result of surgery or chemotherapy. Menopausal women might suffer from hot flashes, exhaustion, depression, lack of concentration, and memory issues.
Market Drivers
The increasing incidences of post-menopausal symptoms owing to the shift towards a hectic lifestyle propel the growth of the market.
The growing prevalence of vasomotor and menopausal symptoms like night sweats and hot flashes among women during the menopausal transition and the issues such as mood swings, difficulty in concentrating, and depression act as major factors for the growing market during the forecast period. Furthermore, rising investment in the treatment of menopausal manifestation boosts the expansion of the market.
The growing technological advancements and modernization in the healthcare sector fuel market growth.
Market Restraints
The lack of awareness among people regarding menopause drugs and the less consciousness among patients hinders the growth of the market.
Furthermore, the lack of advanced healthcare infrastructure facilities restrains the growth of the global menopause drug market.
COVID-19 Impact on Menopause Drug Market
The outbreak of covid-19 negatively impacted the market as restrictions and lockdowns were imposed by the government to protect public health, and the supply chain and production were disrupted. The mental health of the women leads to hormonal imbalance and exaggeration of the vasomotor symptoms which increase the demand for menopause drug products and drive the market during a pandemic.
Impact of Russia Ukraine War on the Market
The conflict between Russia and Ukraine can have both direct and indirect impacts on the menopause drug market:
Disruptions in the supply chain: Many Menopause Drug manufacturers source components from Russia and Ukraine. The war may cause supply chain disruptions and delays, affecting menopause drug production and delivery.
Economic sanctions: Economic sanctions imposed on Russia may have an impact on the overall economy, as well as the demand for menopause drugs in the region.
Market Segmentation
The Global Menopause Drug Market is segmented on the basis of Stages Type, Treatment Type, Product Type, Administration Type, End-Users, and Region. Based on Stages Type, it is segmented into Perimenopause, Menopause, and Postmenopause. On the basis of Treatment Type, it is segmented into Non-Hormonal Treatment, Hormonal Treatment, and Herbal Supplements. Non-Hormonal Treatment is sub-segmented into Paroxetine. Hormonal Treatment is sub-segmented into Estrogen-Only Medicines, Progestin-Only Medicines, and Combination Estrogen, Progestin Medicines. Herbal supplements sub- segmented into Ginseng, Ashwagandha. Based on Product Type, it is segmented into Patch, Pill, Gel, Injectable, Cream, and Others. Based on the Route of Administration Type, it is segmented into Oral, Injectable, and Topical. Based on End-Users, it is segmented into Hospitals, Homecare, Specialty Clinics, and Others. Based on Region, It is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.
Regional Analysis
North America is likely to dominate the market over the forecast period owing to the high incidences of an unhealthy lifestyle, and the rising introduction of novel drugs in this region.
Asia Pacific is also anticipated to witness substantial growth because of the increasingly vulnerable aging population of menopausal women and the increase in the demand for novel therapies in this region.
Key Players
Various key players are listed in this report such as Teva Pharmaceutical Industries Ltd, Eli Lilly and Company, Allergan, Pfizer Inc, Novo Nordisk A/S, Merck & Co Inc, Boehringer Ingelheim International GmbH, Pantarhei Bioscience, F. Hoffmann-La Roche Ltd, GlaxoSmithKline plc, SHIONOGI & Co Ltd, BioSyent Inc, Glenmark Pharmaceuticals Limited, Aché Laboratórios Farmacêuticos SA.
Market Taxonomy
By Stages Type
• Perimenopause
• Menopause
• Postmenopause
By Treatment Type
• Non-Hormonal Treatment
o Paroxetine
• Hormonal Treatment
o Estrogen-Only Medicines
o Progestin-Only Medicines
o Combination Estrogen
o Progestin Medicines
• Herbal Supplements
o Ginseng
o Ashwagandha
By Product Type
• Patch
• Pill
• Gel
• Injectable
• Cream
• Others
By Route of Administration Type
• Oral
• Injectable
• Topical
By End-Users
• Hospitals
• Homecare
• Specialty Clinics
• Others
By Region
• North America
• Europe
• Asia Pacific
• Latin America
• Middle East and Africa
Key Question Addressed by the Report
• What are the Key Opportunities in Global Menopause Drug Market?
• What will be the growth rate from 2023 to 2030?
• Which segment/region will have the highest growth?
• What are the factors that will impact/drive the Market?
• What is the role of key players in the value chain?
Global Menopause Drug Market
1 Introduction
1.1 Objective of the Study
1.2 Market definition
1.3 Market Scope
2 Research Methodology
2.1 Data Mining
2.2 Validation
2.3 Primary Interviews
2.4 List of Data Source
3 Executive Summary
4 Global Menopause Drug Market Outlook
4.1 Overview
4.2 Market Dynamics
4.2.1 Drivers
4.2.2 Restraints
4.2.3 Opportunities
4.2.4 Cumulative Impact due to recent Energy Crisis
4.2.5 Cumulative Impact due to nearing economic downturn
4.2.6 Post covid-19 world Supply& Demand conditions
4.2.7 Cumulative Impact of Russia-Ukraine Conflict
4.3 Porters Five Force Model
4.4 Value Chain Analysis
5 Global Menopause Drug Market, By Stages Type
5.1 Y-o-Y Growth Comparison, By Stages Type
5.2 Global Menopause Drug Market Share Analysis, By Stages Type
5.3 Global Menopause Drug Market Size and Forecast, By Stages Type
5.3.1 Perimenopause
5.3.2 Menopause
5.3.3 Postmenopause
6 Global Menopause Drug Market, By Treatment Type
6.1 Y-o-Y Growth Comparison, By Treatment Type
6.3 Global Menopause Drug Market Share Analysis, By Treatment Type
6.3 Global Menopause Drug Market Size and Forecast, By Treatment Type
6.3.1 Non-Hormonal Treatment
6.3.1.1 Paroxetine
6.3.2 Hormonal Treatment
6.3.2.1 Estrogen-Only Medicines
6.3.2.2 Progestin-Only Medicines
6.3.2.3 Combination Estrogen
6.3.3.4 Progestin Medicines
6.3.3 Herbal Supplements
6.3.3.1 Ginseng
6.3.3.2 Ashwagandha
7 Global Menopause Drug Market, By Product Type
7.1 Y-o-Y Growth Comparison, By Product Type
7.2 Global Menopause Drug Market Share Analysis, By Product Type
7.3 Global Menopause Drug Market Size and Forecast, By Product Type
7.3.1 Patch
7.3.2 Pill
7.3.3 Gel
7.3.4 Injectable
7.3.5 Cream
7.3.6 Others
8 Global Menopause Drug Market, By Route of Administration Types
8.1 Y-o-Y Growth Comparison, By Route of Administration Types
8.2 Global Menopause Drug Market Share Analysis, By Route of Administration Types
8.3 Global Menopause Drug Market Size and Forecast, By Route of Administration Types
8.3.1 Oral
8.3.2 Injectable
8.3.3 Topical
9 Global Menopause Drug Market, By End-Users
9.1 Y-o-Y Growth Comparison, By End-Users
9.2 Global Menopause Drug Market Share Analysis, By End-Users
9.3 Global Menopause Drug Market Size and Forecast, By End-Users
9.3.1 Hospitals
9.3.2 Homecare
9.3.3 Specialty Clinics
9.3.4 Others
10 Global Menopause Drug Market, By Region
10.1 Global Menopause Drug Market Share Analysis, By Region
10.2 Global Menopause Drug Market Share Analysis, By Region
10.3 Global Menopause Drug Market Size and Forecast, By Region
11 North America Menopause Drug Analysis and Forecast (2023-2030)
11.1 Introduction
11.2 North America Menopause Drug Product Market Share Analysis, By Stages Type
11.3 North America Menopause Drug Product Market Size and Forecast, By Treatment Type
11.4 North America Menopause Drug Product Market Size and Forecast, By Product Type
11.5 North America Menopause Drug Product Market Size and Forecast, By Route of Administration Types
11.6 North America Menopause Drug Product Market Size and Forecast, By End-Users
11.7 North America Menopause Drug Product Market Size and Forecast, By Country
11.7.1 U.S.
11.7.2 Canada
11.7.3 Mexico
12 Europe Menopause Drug Market Analysis and Forecast (2023-2030)
12.1 Introduction
12.2 Europe Menopause Drug Product Market Share Analysis, By Stages Type
12.3 Europe Menopause Drug Product Market Size and Forecast, By Treatment Type
12.4 Europe Menopause Drug Product Market Size and Forecast, By Product Type
12.5 Europe Menopause Drug Product Market Size and Forecast, By Route of Administration Types
12.6 Europe Menopause Drug Product Market Size and Forecast, By End-Users
12.7. Europe Menopause Drug Product Market Size and Forecast, By Country
12.7.1 Germany
12.7.2 France
12.7.3 UK
12.7.4. Rest of Europe
13 Asia Pacific Menopause Drug Market Analysis and Forecast (2023-2030)
13.1 Introduction
13.2 Asia Pacific Menopause Drug Product Market Share Analysis, By Stages Type
13.3 Asia Pacific Menopause Drug Product Market Size and Forecast, By Treatment Type
13.4 Asia Pacific Menopause Drug Product Market Size and Forecast, By Product Type
13.5 Asia Pacific Menopause Drug Product Market Size and Forecast, By Route of Administration Types
13.6 Asia Pacific Menopause Drug Product Market Size and Forecast, By End-Users
13.7 Asia Pacific Menopause Drug Product Market Size and Forecast, By Country
13.7.1 China
13.7.2 Japan
13.7.3 India
13.7.4. Rest of Asia Pacific
14 Latin America Menopause Drug Market Analysis and Forecast (2023-2030)
14.1 Introduction
14.2 Latin America Menopause Drug Product Market Share Analysis, By Stages Type
14.3 Latin America Menopause Drug Product Market Size and Forecast, By Treatment Type
14.4 Latin America Menopause Drug Product Market Size and Forecast, By Product Type
14.5 Latin America Menopause Drug Product Market Size and Forecast, By Route of Administration Types
14.6 Latin America Menopause Drug Product Market Size and Forecast, By End-Users
14.7 Latin America Menopause Drug Product Market Size and Forecast, By Country
14.7.1. Brazil
14.7.2. Rest of Latin America
15 Middle East Menopause Drug Market Analysis and Forecast (2023-2030)
15.1 Introduction
15.2 Middle East Menopause Drug Product Market Share Analysis, By Stages Type
15.3 Middle East Menopause Drug Product Market Size and Forecast, By Treatment Type
15.4 Middle East Menopause Drug Product Market Size and Forecast, By Product Type
15.5 Middle East Menopause Drug Product Market Size and Forecast, By Route of Administration Types
15.6 Middle East Menopause Drug Product Market Size and Forecast, By End-Users
15.7 Middle East Menopause Drug Product Market Size and Forecast, By Country
15.7.1. Saudi Arabia
15.7.2. UAE
15.7.3. Egypt
15.7.4 Kuwait
15.7.5. South Africa
16 Competitive Analysis
16.1 Competition Dashboard
16.2 Market share Analysis of Top Vendors
16.3 Key Development Strategies
17 Company Profiles
17.1 Teva Pharmaceutical Industries Ltd
17.1.1 Overview
17.1.2 Offerings
17.1.3 Key Financials
17.1.4 Business Segment & Geographic Overview
17.1.5 Key Market Developments
17.1.6 Key Strategies
17.2 Eli Lilly and Company
17.2.1 Overview
17.2.2 Offerings
17.2.3 Key Financials
17.2.4 Business Segment & Geographic Overview
17.2.5 Key Market Developments
17.2.6 Key Strategies
17.3 Allergan
17.3.1 Overview
17.3.2 Offerings
17.3.3 Key Financials
17.3.4 Business Segment & Geographic Overview
17.3.5 Key Market Developments
17.3.6 Key Strategies
17.4 Pfizer Inc
17.4.1 Overview
17.4.2 Offerings
17.4.3 Key Financials
17.4.4 Business Segment & Geographic Overview
17.4.5 Key Market Developments
17.4.6 Key Strategies
17.5 Novo Nordisk A/S
17.5.1 Overview
17.5.2 Offerings
17.5.3 Key Financials
17.5.4 Business Segment & Geographic Overview
17.5.5 Key Market Developments
17.5.6 Key Strategies
17.6 Merck & Co Inc
17.6.1 Overview
17.6.2 Offerings
17.6.3 Key Financials
17.6.4 Business Segment & Geographic Overview
17.6.5 Key Market Developments
17.6.6 Key Strategies
17.7 Boehringer Ingelheim International GmbH
17.7.1 Overview
17.7.2 Offerings
17.7.3 Key Financials
17.7.4 Business Segment & Geographic Overview
17.7.5 Key Market Developments
17.7.6 Key Strategies
17.8 Pantarhei Bioscience
17.8.1 Overview
17.8.2 Offerings
17.8.3 Key Financials
17.8.4 Business Segment & Geographic Overview
17.8.5 Key Market Developments
17.8.6 Key Strategies
17.9 F. Hoffmann-La Roche Ltd
17.9.1 Overview
17.9.2 Offerings
17.9.3 Key Financials
17.9.4 Business Segment & Geographic Overview
17.9.5 Key Market Developments
17.9.6 Key Strategies
17.10 GlaxoSmithKline plc
17.10.1 Overview
17.10.2 Offerings
17.10.3 Key Financials
17.10.4 Business Segment & Geographic Overview
17.10.5 Key Market Developments
17.10.6 Key Strategies
17.11 SHIONOGI & Co Ltd
17.11.1 Overview
17.11.2 Offerings
17.11.3 Key Financials
17.11.4 Business Segment & Geographic Overview
17.11.5 Key Market Developments
17.11.6 Key Strategies
17.12 BioSyent Inc
17.12.1 Overview
17.12.2 Offerings
17.12.3 Key Financials
17.12.4 Business Segment & Geographic Overview
17.12.5 Key Market Developments
17.12.6 Key Strategies
17.13 Glenmark Pharmaceuticals Limited
17.13.1 Overview
17.13.2 Offerings
17.13.3 Key Financials
17.13.4 Business Segment & Geographic Overview
17.13.5 Key Market Developments
17.13.6 Key Strategies
17.14 Aché Laboratórios Farmacêuticos SA
17.14.1 Overview
17.14.2 Offerings
17.14.3 Key Financials
17.14.4 Business Segment & Geographic Overview
17.14.5 Key Market Developments
17.14.6 Key Strategies
